Etiketter

lördag 4 mars 2023

ADAMTS-13 ja ADAMTS-13- vasta-aineet täsmädiagnostiikassa

https://www.researchgate.net/journal/Rambam-Maimonides-Medical-Journal-2076-9172 

Thrombotic microangiopathies (TMAs) comprise a group of distinct disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis. For many years distinction between these TMAs, especially between thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), remained purely clinical and hard to make. Recent discoveries shed light on different pathogenesis of TTP and HUS. Ultra-large von Willebrand factor (UL-VWF) platelet thrombi, resulting from the deficiency of cleavage protease which is now known as ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), were found to cause TTP pathology, while Shiga toxins or abnormalities in regulation of the complement system cause microangiopathy and thrombosis in HUS. TMAs may appear in various conditions such as pregnancy, inflammation, malignancy, or exposure to drugs. These conditions might cause acquired TTP, HUS, or other TMAs, or might be a trigger in individuals with genetic predisposition to ADAMTS-13 or complement factor H deficiency. Differentiation between these TMAs is highly important for urgent initiation of appropriate therapy. Measurement of ADAMTS-13 activity and anti-ADAMTS-13 antibody levels may advance this differentiation resulting in accurate diagnosis. Additionally, assessment of ADAMTS-13 levels can be a tool for monitoring treatment efficacy and relapse risk, allowing consideration of therapy addition or change. In the past few years, great improvements in ADAMTS-13 assays have been made, and tests with increased sensitivity, specificity, reproducibility, and shorter turnaround time are now available. These new assays enable ADAMTS-13 measurement in routine clinical diagnostic laboratories, which may ultimately result in improvement of TMA management.

tisdag 23 november 2021

Zinkiinit , Metzinkiinit, Metalloproteaasit (MP)

 (Miten löysin tämän artikkelin tnään 23.11.2021: Olin etsimässä Sars-2 S-proteiinin  trimerisoitumisesta ensinnä arikkeleita ja siten  aloin pohtia  transmembraanisen  trimeroituneen tyven muodostumista ja etsiäö prokollageenin  trimerisoivaa domeenia; - samalla löysin  entsyymejä- , jotka pilkkovat tässä yhteydessä   mahdollista  trimeeriä koska se on transientti  fysiologisesti. Tosin sars-2  ei anna  trimeerien pilkoutua ainakaan ennen kuin uudet virionit ovat valmiita stabiilien trimeerien kanssa  ja toisaalta   infektoituminen  vanhalla trimeerillä on tehty.   Löysin siitä  fokuksesta  molekyylejä, jotka ovat  Sars-2 interaktioproteiineja ja samalla rokotevalmstuksessakin tarvittava. Yhdessä oli CUB-domeeni ja NTR-domeeni vapautui siitä   pilkkoutumalla. NTR-modulista sanottiin, että se oli " homologinen TIMP:n kanssa, mutta ei pystynyt  vaikuttamaan  metsinkiineihin".  Sen takia  etsin metsinkiinit esiin . Niin läysin tämän artikkelin). 

 

 

 https://www.jbc.org/article/S0021-9258(20)42509-8/fulltext

 

Minireviews| Volume 284, ISSUE 23, P15353-15357, June 2009

Catalytic Domain Architecture of Metzincin Metalloproteases

Metalloproteases cleave proteins and peptides, and deregulation of their function leads to pathology. An understanding of their structure and mechanisms of action is necessary to the development of strategies for their regulation. Among metallopeptidases are the metzincins, which are mostly multidomain proteins with ∼130–260-residue globular catalytic domains showing a common core architecture characterized by a long zinc-binding consensus motif, HEXXHXXGXX(H/D), and a methionine-containing Met-turn. Metzincins participate in unspecific protein degradation such as digestion of intake proteins and tissue development, maintenance, and remodeling, but they are also involved in highly specific cleavage events to activate or inactivate themselves or other (pro)enzymes and bioactive peptides.
 Metzincins are subdivided into families, and seven such families have been analyzed at the structural level: 
the astacins,
 ADAMs/adamalysins/reprolysins,
 serralysins,
 matrix metalloproteinases (MMPs) ,
 snapalysins, 
leishmanolysins, and
 pappalysins. 
These families are reviewed from a structural point of view.

Metalloproteases

Cleavage of peptide bonds is essential for life, and the factors responsible for peptide cleavage are ubiquitous. Among them are MPs, which are mostly zinc-dependent peptide-bond hydrolases. They participate in metabolism through both extensive and unspecific protein degradation and controlled hydrolysis of specific peptide bonds ().   Deregulation of such vast degrading potential leads to pathologies, and in addition, MPs may also act as virulence factors during poisoning and microbial infection. Such a wide range of biological functions makes structural studies of these proteins indispensable to any understanding of their function and to the design of novel, highly specific therapeutic agents to modulate their activity ().
Most MPs are members of a protease tribe, the zincins, and they possess a short consensus amino acidsequence, HEXXH. This motif contains two protein ligands of the catalytic zinc and a glutamate that acts as general base/acid during the catalytic process (,). A third metal ligand is a solvent molecule, further bound to and polarized by the glutamate. This solvent performs nucleophilic attack on the carbonyl carbon of the scissile bond of a bound substrate, leading to a tetrahedral gem-diolate reaction intermediate, which is stabilized by the positively charged metal ion and neighboring protein residues (). Subsequent evolution of the intermediate under assistance of the general base/acid eventually leads to bond disruption.
Zincins are divided into the
 gluzincin,
 aspzincin, and
 metzincin clans (,).
 The latter contains mostly multidomain proteins with an N-terminal prodomain engaged in latency maintenance, a catalytic protease domain, and farther downstream domains engaged in protein-protein and cell-cell interactions and other regulatory functions. The protease domain is characterized by a C-terminally extended zinc-binding motif, HEXXHXXGXX(H/D), with a hallmark glycine and a third zinc-binding histidine or aspartate. In addition, a methionine is present in a conserved downstream turn, the Met-turn (,,).
 Metzincins split into families, seven of which have been characterized at the structural level for at least one of their members: astacins, ADAMs/adamalysins/reprolysins, serralysins, matrix metalloproteinases, snapalysins, leishmanolysins, and pappalysins.
 In addition, a series of sequences reported from genome sequencing projects indicate there are further structurally yet uncharacterized families, tentatively referred to as
 fragilysins,
 gametolysins,
 archaemetzincins,
 thuringilysins, 
 coelilysins,
 ascomycolysins,
 helicolysins, and 
cholerilysins (for a detailed review, see Ref.).

The Metzincin Fold

To date, >200 structures of metzincins, comprising at least the catalytic domain, have been deposited with the Protein Data Bank (supplemental Table 1). In this review, seven lead structures of each of the aforementioned families are discussed: Astacus astacus astacin, Crotalus adamanteus adamalysin II, Pseudomonas aeruginosa aeruginolysin, human neutrophil collagenase (MMP-8), Streptomyces caespitosus neutral protease (snapalysin), Leishmania major leishmanolysin, and Methanosarcina acetivorans ulilysin (,,,,,,). These prototypes cover distinct kingdoms of life and represent archaea, bacteria, protozoa, crustaceans, reptiles, and mammals. The structures reveal that metzincins share a common scaffold and active-site environment, but each family has distinguishing structural elements. Mature catalytic domains are ∼130–260-residue globular moieties that bifurcate into an upper NSD and a lower CSD with respect to a central active-site cleft. Substrates bind horizontally to this cleft from left to right in an approximately extended conformation (supplemental Fig. 1 A). (All topological indications refer to the standard orientation displayed in this figure.)

 

The NSD displays a five-stranded twisted β-sheet at the top (except leishmanolysin, which has four strands) (supplemental Fig. 1A). All strands (βI–βV) except the fourth are parallel to each other and to any substrate that is bound in the cleft. The antiparallel strand, βIV, forms the lower edge of this subdomain and creates an upper rim or northern wall of the active-site crevice (). This strand binds a substrate in an antiparallel manner, mainly on its non-primed side. The loop segment connecting strands βIII and βIV (referred to as LβIIIβIV) leads to the appearance of bulge-like elements, which mainly affect subsites S1′ and S2′ (see Ref. for subsite nomenclature in proteases). This gives rise to extensive variations in enzyme-substrate interactions on the primed side of the active-site clefts. The NSD also contains two long α-helices, αA and αB, the backing helix and the active-site helix, respectively. Both are arranged on the concave side of the β-sheet in an identical manner in all metzincin structures (supplemental Fig. 1B). Helix αB superimposes well in all seven structures (Fig. 1A) and encompasses the first half of the zinc-binding motif, which includes the first two zinc-binding histidine residues (Fig. 1A and supplemental Fig. 1). At the end of helix αB, the polypeptide chain takes a sharp downward turn, mediated by the glycine of the consensus sequence. The main-chain angles of this residue in the different lead structures indicate that any other residue would be in a high-energy conformation and thus disfavored, with the exception of ulilysin (see below).

 

FIGURE 1Overlay of structural segments common to the seven prototypes as Cα plots. A, the active-site helix αB (including the side chains of the zinc-liganding histidines and aspartate and the general base/acid) and the Met-turn (with the methionine side chain). Blue, astacin; cyan, adamalysin II; red, leishmanolysin; green, MMP-8; white, aeruginolysin; yellow, snapalysin; orange, ulilysin. The magenta curved arrows indicate where an extra domain is inserted in leishmanolysin. B, the upper domain β-sheet (strands βI–βV, in cyan, blue, green, orange, and yellow, respectively), the posterior helix αA (red), and the C-terminal helix αC (purple) as found in the seven leads. Leishmanolysin lacks strand βII.
The CSD starts after this glycine, and the chain leads to the third zinc ligand, a histidine or an aspartate, which approaches the metal from below (supplemental Fig. 1). This subdomain contains few repetitive secondary structure elements, mainly a C-terminal helix αC at the end of the polypeptide chain. Helices αB and αC are connected by structures that vary both in length and conformation. However, all structures coincide at a conserved 1,4-β-turn containing a methionine at position 3, the Met-turn, which is separated from the third zinc-binding histidine by connecting segments of 6–53 amino acids in the different structures. The Met-turn is superimposable (including the conformation of the methionine side chain) (Fig. 1A) and is positioned underneath the catalytic Zn2+, forming a hydrophobic pillow. However, no direct contact with the metal is observed. Mutation studies suggested a role for this methionine in the folding and stability of the catalytic domains, although the strict conservation of this residue remains to be explained (,). The S1′ pocket of metzincins is shaped at the top by a protruding bulge made by LβIIIβIV and at the bottom by a wall-forming segment made up of residues intercalated between the Met-turn and the C-terminal helix αC (). This segment diverges in structure and length (ranging from 11 to 37 residues between the Met-turn methionine and the first residue of helix αC) in all seven of the reference structures.

The Zinc-binding Site

The catalytic zinc ion lies roughly at the center of the bottom of the active-site cleft. It is coordinated by the Nϵ2 atoms of the three consensus histidines (two histidine Nϵ2 atoms and one aspartate Oδ2 atom in snapalysin) and the catalytic solvent molecule, substituted by other ligands in the enzyme/inhibitor-product complexes reported (supplemental Table 1). Some metzincins display an additional protein ligand at a slightly greater distance from the catalytic cation in the form of a tyrosine Oη atom, as seen in unbound astacin and serralysins and as hypothesized in ulilysin (). This tyrosine residue lies two positions ahead of the Met-turn methionine. In (unbound) snapalysin, a tyrosine lies two positions downstream of the metal-binding aspartate, though no longer within binding distance of the zinc ion. These tyrosine residues flip back and forth during substrate anchoring, cleavage, and product release in a motion referred to as the tyrosine switch. In this, they may play a role in substrate and catalytic solvent binding and stabilization of the tetrahedral intermediate or the product amino group (
,,,,). Such a role is performed by other, non-conserved residues in tyrosine-lacking metzincins.

Structural Relatedness among Families

A structure-based sequence alignment reveals that, with the exception of the region comprising the zinc-binding consensus sequence, sequence identity is negligible among metzincins despite evident structural relatedness. Based on this alignment, pairwise comparisons between leads (supplemental Fig. 2) show between 41 and 118 topologically equivalent Cα positions and root mean square deviations between 3.3 and 4.0Å, i.e. above the threshold at which two Cα positions can be considered as structurally equivalent (3.0 Å) (
). The sequence identities range between 3 and 20%, i.e. clearly below twilight values for sequence relatedness (25–35%) (). The closest structural pairs are aeruginolysin and MMP-8 (Z-score = 15.8) (supplemental Fig. 2 and supplemental Refs.and), MMP-8 and snapalysin (15.2), adamalysin II and ulilysin (14.4), and adamalysin II and leishmanolysin (14.3). The most distant pairs are astacin and adamalysin II (Z-score = 2.9), MMP-8 and ulilysin (.2), and snapalysin and ulilysin (6.6).

Distinguishing Features of Each Family

Astacin is a 200-residue digestive enzyme from the crayfish A. astacus and the first member of the astacin family to be structurally analyzed (). Through protein degradation, growth factor activation, extracellular matrix turnover, and extracellular coat degradation (hatching), astacins participate in diverse biological processes such as digestion, development, and tissue remodeling and differentiation (e.g. promoting cartilage and bone formation and collagen biosynthesis) ().The three-dimensional structure of astacin shows a packman-like spherical shape and two subdomains of approximately equal size (supplemental Fig. 1A) (). Whereas this proteinase contains only a propeptide and a catalytic MP domain, most other astacins display additional C-terminal MATH, MAM, CUB-like, Ser/Thr-rich, I (inserted)-, epidermal growth factor-like, Tox1, and transmembrane modules (for details, see Refs.
,, and). The astacin family has the longest region of the CSD lacking regular secondary structure elements, just a small helix and a short β-ribbon, although this is the sequentially most conserved connecting segment among metzincins (see Table 1 in Ref.). The protein scaffold is cross-linked by four conserved cysteine residues forming two disulfide bridges (supplemental Fig. 1). The first two residues of the mature enzyme are buried in an internal cavity in the CSD, and the N-terminal α-amino group establishes an interaction with a conserved glutamate next to the third zinc-binding histidine. The unbound coordination of the catalytic zinc is trigonal-bipyramidal due to the presence of the fourth invariant, although somewhat more distal, tyrosine zinc ligand downstream of the Met-turn (supplemental Fig. 1A). In addition to astacin, the structures of human tolloid-like protease-1 and bone morphogenetic protein-1 have recently been reported ().
 
Serralysins are ∼50-kDa bacterial virulence factors secreted as autoactivatable zymogens by pathogenic γ-class proteobacteria (). These organisms are responsible for human diseases such as meningitis, endocarditis, pyelonephritis, plague, dermatitis, soft tissue infections, septicemia, melioidosis, pneumonia, and other respiratory and urinary tract infections. They play a major role in hospital-acquired infections due to their capacity to produce surgical wound infections and to infect neonates. As part of the virulence potential of these bacteria, serralysins are directed against coagulation factors and defense-oriented proteins, protease inhibitors, lysozyme, and transferrin and may cause an anaphylactic response.
The first serralysin to be biochemically and structurally characterized was P. aeruginosa aeruginolysin (
). Its mature 220-residue catalytic domain lacks disulfide connections and is flanked on its C-terminal end by a calcium-stabilized β-roll domain. As in astacin, its two subdomains are of similar size. The polypeptide chain starts with an α-helix in the CSD (characteristic for the family) that is anchored to the molecular body by a conserved salt bridge with the C-terminal helix αC (supplemental Fig. 1B). The NSD features a flap made up by an elongated LβIαA and runs across the convex surface of the β-sheet. This flap varies greatly among serralysins (20 reported structures) (supplemental Table 1), distinctly affecting substrate binding. The CSD of aeruginolysin presents an extra α-helix within the segment linking the Met-turn with the wall-forming stretch and a second flap shaped by residues of the connecting segment. These elements also modulate substrate binding. Comparison of aeruginolysin, which was first solved in complex with a bound tetrapeptide (), with the closely related structure of unbound Serratia marcescens serralysin reveals that the unliganded zinc coordination is similar to astacin (trigonal-bipyramidal). It also includes a tyrosine that undergoes a hinge motion upon substrate binding ().
 
S. caespitosus snapalysin is a secreted neutral protease that comprises a 132-residue catalytic domain preceded by an alanine-rich 100-amino acid N-terminal extension including a signal peptide and a prodomain. Similar sequences have been reported for other Streptomyces species, and they have been termed SnpA (Prt and snapalysin), MprA, and SnpA. They show milk-hydrolyzing activity.
Snapalysin is the smallest metzincin and the only family member that has been structurally characterized. Its structure recalls a flattened ellipsoid and bifurcates into two asymmetric subdomains (
). It displays all the characteristic metzincin features, connected by short loops. Distinguishing elements are a small LβIIβIII protruding from the upper sheet within the NSD, a small bulge on top of the primed side of the active-site crevice, a short helix in LβVαB, and a calcium-binding site (supplemental Fig. 1A). In addition, an aspartate is found at the position of the third zinc-binding histidine, and two positions ahead in the sequence, a conserved tyrosine approaches but not binds the metal.
 
MMPs are secreted or membrane-bound proteinases discovered 47 years ago and participate in tail resorption during tadpole-to-frog metamorphosis. They are found mainly in higher mammals, although related sequences have been found in fish, amphibians, insects, plants, prokaryotes, and viruses. Through turnover of extracellular matrix proteins, MMPs are involved in tissue resorption, remodeling, and repair, as observed during embryogenesis and development, branching and organ morphogenesis, and angiogenesis. However, their potent proteolytic potential or its absence may also lead to pathologies such as inflammation, ulcers, rheumatoid arthritis and osteoarthritis, periodontitis, heart failure and cardiovascular disease, fibrosis, emphysema, and cancer and metastasis (). More recently, MMPs have been observed to be engaged in (in)activation events following limited proteolysis, as observed in apoptosis and intestinal defense protein activation but also in pathologies including stroke, human immunodeficiency virus-associated dementia, atherosclerosis, multiple sclerosis, bacterial meningitis, and Alzheimer disease. MMPs include extracellular proteins such as other (pro)proteinases, inhibitors, clotting factors, antimicrobial peptides, and chemotactic and adhesion molecules. In common with ADAMs (see below), MMPs are also involved in ectodomain shedding of growth factors, growth factor-binding proteins, hormones and hormone receptors, and cytokines and cytokine receptors from the cell surface ().
Like other metzincin families, MMPs are mosaic proteins constituted by a series of inserts and domains. These may include an ∼20-residue secretory signal peptide, an ∼80-residue propeptide, a 160–170-residue zinc- and calcium-dependent catalytic proteinase domain, a linker region, and a 4-fold propeller hemopexin-like C-terminal domain. Further insertions may include fibronectin type II-related domains; a collagen type V-like and vitronectin-like insertion domain; a cysteine-rich, a proline-rich, and an interleukin-1 receptor-like domain; an immunoglobulin-like domain; a glycosylphosphatidylinositol linkage signal; a membrane anchor; and a cytoplasmic tail. Naming of MMPs started historically with fibroblast collagenase as MMP-1 and has currently reached MMP-28, with 23 different forms described in humans (). Those MMPs encompassing a membrane anchor gave rise to the membrane-type MMP subfamily (,). Zymogen activation proceeds in MMPs according to a cysteine switch or Velcro mechanism. This removes the prodomain and switches from an inactive state, where the Sγ atom of a cysteine residue within a conserved motif, PRCGVPD, substitutes the catalytic solvent molecule in the zinc coordination sphere, to the fully accessible active enzyme (,). MMPs are the structurally most thoroughly studied metzincin family, with >120 structures reported (supplemental Table 1) (). The mature catalytic domain of human neutrophil collagenase (MMP-8) (,) has a shallow active-site cavity, which separates a larger NSD (∼120 residues) from a smaller CSD (∼40 amino acids), and generally a deep hydrophobic S1′ pocket. No disulfide bonds are present in the structure. The N-terminal α-amino group is anchored to the first of two conserved aspartates imbedded in helix αC. The NSD displays an S-shaped double loop connecting strands βIII and βIV, which embraces a structural zinc cation and a tightly bound calcium ion. The downstream residues of this segment form a prominent bulge that protrudes into the active-site groove. LβIVβV and LβIIβIII contribute to a second calcium-binding site on top of the NSD β-sheet (supplemental Fig. 1, A and B). In the CSD, the MMP-8 chain displays the shortest and most conserved connecting segment within metzincins.
 
ADAMs/adamalysins/reprolysins split into three subgroups,
 the snake venom MPs, 
the mammalian ADAMs, and
 the likewise mammalian ADAMTSs (,,,). 
 The former are responsible for post-envenomation hemorrhage through digestion of extracellular matrix components surrounding capillaries, resulting in tissue necrosis. 
In turn, ADAMs were originally described to play a role in fertilization and sperm function in mammalian reproductive tracts. They are involved in myogenesis, development, neurogenesis, differentiation of osteoblastic cells, cell migration modulation, and muscle fusion. They are also engaged in human disorders like asthma, cardiac hypertrophy, obesity-associated adipogenesis and cachexia, rheumatoid arthritis, endotoxic shock, inflammation, and Alzheimer disease. They also have a major role in protein ectodomain shedding as described previously for MMPs.
 Finally, some family members lacking the transmembrane domain and harboring multiple copies of a thrombospondin 1-like repeat and a CUB domain gave rise to a distinct subfamily of soluble extracellular proteases, the ADAMTSs (). These enzymes disable cell adhesion by binding to integrins. They are also involved in gonad formation, embryonic development and angiogenesis, and procollagen activation, as well as in inflammatory processes, cartilage (aggrecan) degradation in arthritic diseases, bleeding disorders, and glioma tumor invasion.
All ADAMs/adamalysins/reprolysins are extracellular multidomain proteins containing a catalytic zinc- and calcium-dependent MP domain. In addition, they can display a prodomain and C-terminal disintegrin-like, cysteine-rich, C-type lectin, epidermal growth factor-like, thrombospondin 1-like, and/or transmembrane domains, as well as a cytoplasmic domain. Latency is maintained by the prodomain, and activation is believed to occur as in MMPs, i.e. by cleavage of the prodomain according to a cysteine switch-like mechanism (,,). 
The first catalytic domain structure to be analyzed was that of adamalysin II from C. adamanteus snake venom (). This is a compact 203-residue molecule of oblate ellipsoidal shape, notched at the periphery to render a relatively flat substrate-fixing cleft. This cleft separates a large ∼150-residue NSD from a small ∼50-residue CSD (supplemental Fig. 1A). Both the N and C termini are surface-located; the former is linked by a salt bridge to the C-terminal helix αC (). Adamalysin II deviates most from the metzincin consensus sequence within the conserved regular secondary structure elements, especially at strand βI and helices αA and αC (Fig. 1B). Inserted into the common scaffold, two additional helices are found within the NSD. In the CSD, two disulfide bonds cross-link the irregular connecting segment and attach helix αC to the NSD, respectively. A calcium ion is located on the surface, opposite the active site and close to the C terminus (supplemental Fig. 1A). The S1′ pocket, characterized by a pronounced bulge segment LβIVβV, is hydrophobic and deep, reminiscent of some MMPs.
 In addition to adamalysin II, a number of snake venom MPs (ADAM-17, ADAM-33, and ADAMTS-1, -4, and -5) have been structurally analyzed to date (supplemental Table 1).
 
Leishmanolysins are cell-surface proteins present in most trypanosomatid, plasmodiid, and sarcocystid protozoa. They constitute the major component of the promastigote surface and are enzymatically active against polypeptide substrates. They cleave CD4 molecules at the surface of human T cells and protect promastigotes from lysis by complement proteins, suggesting a possible role as a virulence factor. Related sequences have been found in mammals (here called invadolysin), fruit flies, thale cress, nematodes, and bacteria (,). 
The only structurally analyzed family member is L. major leishmanolysin. It is synthesized as a 602-residue inactive precursor in the endoplasmic reticulum with a signal and a 100-residue propeptide, which includes a highly conserved cysteine residue potentially acting as a cysteine switch (see above). Activation liberates a mature MP of ∼280 residues, followed by an ∼200-residue C-terminal domain. A 63-residue insertion domain is observed between the glycine and the third zinc-binding histidine of the long consensus motif (supplemental Fig. 1A). The MP domain is the most asymmetric among metzincins, with a 175-residue NSD and just an ∼45-amino acid CSD. Its N terminus is located on the back left surface. The NSD is characterized by a β-sheet, which lacks strand βII (supplemental Fig. 1, A and B), and by the presence of two unique ∼40-amino acid inserted flaps, which account for most of the differences in size from the other proteins of the clan. The NSD is cross-linked by two disulfide bonds. Preceding strand βIV, a slightly prominent bulge segment lies on top of the shallow, medium-sized S1′ pocket, which is delimited by the wall-forming segment and the beginning of the active-site helix αB. At the end of the CSD, helix αC is followed by a segment in an extended conformation, which runs from left to right across the back surface ().
 
The most recent family to be structurally characterized are the pappalysins. They were named after human PAPP-A, a heavily glycosylated 170-kDa multidomain protein specifically cleaving insulin-like growth factor-binding proteins (). Proulilysin is a 38-kDa archaeal protein from M. acetivorans that shares sequence similarity with PAPP-A, but it encompasses only the prodomain and the catalytic domain (). The proprotein may undergo cysteine switch-mediated activation, as suggested by the presence of a conserved cysteine in the prodomain. Activation occurs autolytically in the presence of calcium. 
 
With 262 residues, mature ulilysin is the largest MP of all metzincin catalytic domains. As distinguishing features, it presents in the NSD a loop dividing strand βII into two substrands (βII and βII′) and a β-ribbon inserted within LβIIIβIV that protrudes from the molecular surface and frames the active site on its primed side. The segment connecting helix αA with strand βII is the largest among metzincins and covers almost all of the back of the molecule from the NSD to the CSD in a cape-like fashion and includes two unique α-helices. The glycine of the zinc-binding motif is replaced in ulilysin and a small subset of pappalysins by an asparagine under slight variation of the main-chain angles, which do not correspond here to a high-energy conformation but to a left-handed α-helix. Overall, the chain trace flanking this residue is indistinguishable from other metzincins (supplemental Fig. 1) (). The CSD shows two disulfide bonds and a unique two-calcium site. This site is a molecular switch for activity, as the proteinase can be reversibly inhibited through calcium chelators ( ,,). Finally, in the absence of an unbound structure, ulilysin may possess a fifth zinc-binding tyrosine ligand provided by the Met-turn that is swung out upon substrate binding.

Conclusions

The metzincins constitute a clan of ubiquitous MPs present in all kingdoms of life, which are pivotal for physiology and pathology. So far, seven families have been structurally analyzed. The clan represents a case of divergent evolution from an urmetzincin, which may not look very different from the smallest member, snapalysin. Into such a minimal scaffold, evolution has introduced unique structural elements conserved among each family. Based on the presence of an extended zinc-binding consensus sequence pattern, several more families have been suggested to enlarge the clan, although future structural analysis will be required to confirm their ascription. Structural information on each of the seven families may help to elucidate common catalytic and processing mechanisms and to assign the function of proteins encoded by newly discovered gene sequences.

Acknowledgments

I thank Robin Rycroft for help

tisdag 19 oktober 2021

COVID-19 ja ADAMTS-19

 https://www.practiceupdate.com/content/adamts13-regulation-of-vwf-multimer-distribution-in-severe-covid-19/119629

ADAMTS13 ja vWf. Hematologiset taudit iTTP ja hTTP.Tromboottiset trombosytopeniset purpuramuodot.

 Löydän tänään tulleesta tanskalaisesta lääkärilehdestä hematologia käsittelevien artikkeleiden joukosta  myös ADAMTS13 geeniä käsittelevää. 

Hansen,A C Nilsson, Henrik Fredriksen. Trombotisk trombocytopeniskt purpura TTP tai TMA.

TTP on disseminoitunutta mikrotrombimuodostusta luonteeltaan. TTP on akuutti, henkeä uhkaava tromboottinen mikroangiopatia. Tilaa aiheuttaa ADAMTS13- entsyymin puute.

Tieteen edistyminen  on lähinnä tilanteen arvioinnin ja täsmällisen  biokemiallisen diagnostiikan ja  hoidon  optimoitumista.

Seuranta vaatii ADAMTS13-entsyymiaktiiviteetin monitorointia. Myös psykiatriset ja kognitiiviset  seuraamuksetkin on otettava huomioon.

Taudilla on kaksi muotoa iTTP ja hTTP

iTTP,  hankittu  autoimmuunitauti, jossa immunoglobuliini G-autovasta-aineet kohdistuvat ADAMTS13-proteaasientsyymiin, joilloin siitä tulee puutetta tavalla tai toisella: joko entsyymin aktiivisuus estyy tai sen vaihtuminen kiihtyy.

hTTP, hereditäärinen, perinnöllinen  tautimuoto johtunee resessiivisesti periytyvistäå mutatoituneista ADAMTS13 geeneistä ADAMTS13-entsyymin aktiivisuus on tällöin alentunutta.  Tämä  hTTP on harvinaista. Sitä on 5%:ssa kaikista TTP-tapauksista. Naisilla esiintyy useammin TTP.

Kertausta  ADAMTS13 proteaasin  fysiologisesta tehtävästä:

ADAMTS13 pilkkoo  vW-faktorin molekyylejä, kun niitä  alkaa ultrapitkinä  vapautua endoteelisoluista ja saa aikaan monomeerimuotoja.

ADAMTS13- entsyymin puutteessa jää vW-faktorista pitkiä  muotoja , jotka takerruttavat  verihiutaleita toisiinsa  aiheuttaen  mikrotrombeja. Tämä  voi tapahtua myös juoksevassa  veressä jossa ei ole  paikallisvauriota. Siis ilmiö voi olla disseminoitua.Koska nyt  aggrekoituu  trombosyyttejä, niistä tulee  puutetta vähitellen: konsumptiosytopenia , lisäksi vielä punasolujen mekaanista vaurioitumista Kliinisesti tilanne ilmenee hemolyyttisenä anemiana ja trombosytopeniana ja fluktuoivina   elinvaikutuksina, joista heijastuu mikrotrombien muodostuminen ja  liukeneminen. 

Kolmasosalla potilaista esiintyy myös neurologisia oireita.päänsärkyä,  TIA-oiretta,jopa halvausta, koko aivokuoren antamaa affektiivista oireilua tai tajuttomuutta. Kolmasosalla esiintyy kuumetta, pahoinvointia ja mahakipuja.  Munuaisfunktiossa voi olla vaikutusta n 40%:lla, useimmiten  vain lievästi kohonneita kreatiniinipitoisuuksia. Kuitenkin dialyysitarvetta on  1-2%:lla. 

60%:lla iTTP -potilaista ei esiinny  toisen tekijän  liittymistä tilaan, Useimmiten assosioituvia ovat jokin toinen autoimmuniteetti, infektio   tai raskaudentila. 

Verenkuvan piirteitä TTP-potilailla:

Aina trombosytopenia ja merkkejä mikroangiopaattisesta hemolyyttisestä anemiasta, jossa on matala hemoglobiinipitoisuus,matala haptoglobiinitaso, korkea retikulosyyttipitoisuus, korkea  vapaa hemoglobiini-, bilirubiini-ja laktaattidehydrogenaasipitoisuus sekä lisääntynyt määrä fragmentoituneita punasoluja(skistosyyttejä).

Koagulaatiotekijät ovat normaaleja ja suora antiglobuliinitesti on negatiivinen. ADAMTS13- entsyymipitoisuudet ovat alle 10% normaalista. (ref.40-130%)  iTTP-tapauksissa todetaan myös ADAMTS13- autovasta-aineita. 

Elinvaikutus voi heijastua esim troponiini ja kreatiniinipitoisuuksien kohoamisissa.

CT/MR on tyypillisesti normaali komatoosissakin  tilassa.

Hoito:Plasmanvaihto, jolla vähennetään  ADAMTS13- autovasta-aineita. ADAMTS13- entsyymin anto.  Kortikosteroideja, Rituximab, Caplacizumab.

ugeskriftet.dk 18.oktober 2021

Ugeskr Laeger2021;183;V03210230


lördag 20 februari 2021

Jänteen kehityksestä. Tenosyyttisolut. Metalloproteinaasien MMP ja ADAMTS metalloproteaasien osuudesta.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689213/

 

 

 

Covid-19 ja  nivelet, jänteet?


Col6A1

Interactome  Sars-2 , Human trofoblast 

file:///C:/Users/Laatikko/AppData/Local/Temp/preprints202005.0333.v1.pdf

 

 


onsdag 29 april 2020

Keltainen skorpioni, deathstalker scorpion

https://www.nyp.org/deathstalkerscorpion/scorpion_facts.html
Scorpion Facts
The Deathstalker (Leiurus quinquestriatus), is a species of scorpion, a member of the Buthidae family. It is also known as an Omdurman scorpion, or Israeli desert scorpion. The name Leiurus quinquestriatus roughly translates to “five-striped smooth-tail”. Other species of the genus Leiurus are often referred to as “deathstalkers” as well.
The Deathstalker is straw yellow in color, and can grow 3.5 to 4.5 inches (9 to 11.5 cm) in length. It is of a slight build compared to other scorpions, with a long thin tail and slender pedipalps. A dark segment on the tail is sometimes faint or even missing, which can complicate identification.
Most scorpions have a life span of two to six years.
Deathstalker scorpions are very small often tan or reddish colored with small weak pincers. The stinger tip and pincer tips can be darker, almost black colored. Females are larger than males to accommodate reproductive tasks.
Deathstalker scorpions can be found (if one is foolhardy enough to look for one) in dry desert areas and dry scrublands in northern Africa and the Middle East. It prefers a dry climate, and makes its home in natural burrows or under stones.
Scorpions may capture their prey with their pincers but in the case of the Deathstalker, the pincers are fairly weak so a sting must be administered quickly.
The size of the pincers of a scorpion can be a good measure of the potency of its venom. Scorpions with large, powerful pincers have no need for powerful toxins. Scorpions with small, weak pincers need to have strong poisons to subdue their prey and ward off enemies.
The Deathstalker scorpion has the strongest poison of any scorpion. If stung, a person will experience extreme pain, convulsions, paralysis and even death due to heart and respiratory failure.

 https://sverigesradio.se/sida/artikel.aspx?programid=406&artikel=5190601
 https://www.youtube.com/watch?v=mms2tTXLWZk

onsdag 26 februari 2020

MME(3q25.2) NEP ( Neprilysiini) , CD10 , membraanimetalloendopeptidaasi

Olen kertaamassa  RAAS- järjestelmää ja siinä on neprilysiinillä (NEP)  myös osa. 
ACE2 ja neprilysiini kehkeyttävät  angiotensiiniä Ang -(1-7)  . ACE2 tekee   sitä muodosta Ang-(1-8), joka on Angiotensiini-II.  Neprilysiini muodostaa sitä  Ang-(1-10).stä,  joka on Angiotensiini-I.  Ang-(1-7)  toimii renoprotektiivisesti ja kardioprotektiivisesti  ja käyttää GPCR-MAS aktivaatiotietä, joka  tie  opponoi ja vaimentaa   ACE- Angiotensiini II- välitteisen   verenpaineen säätelytien  monipuolisia reseptorivaikutuksia ja täten molemmat tiet osallistuvat verenpaineen säätelynhomeostaasiin. 
 
MME-geenin koodama neprilysiini (NEP) on tyypin II transmembraaniglykoproteiini ja  se tunnetaan myös  tavallisena akuutin leukemian antigeenina (CALLA) tärkeänä solupintamerkitsijänä diagnosoitaessa  akuuttia lymfaattista leukemiaa. koodautunutta proteiinia on  pre-B-fenotyyppisissä leukemisissa soluissa, joita on  85% ALL-solusita. Proteiini ei ole kutienkaan rajoittunut leukemisiin soluihin vaan sitä löytyy useissa normaalikudoksissa. proteiini on neutraali endopeptidaasi, joka  pilkkoo peptidejä hydrofobisten aminohappojen  aminopuoellta ja pystyy inaktivoimaan useita peptidihormoneja8 glukagonia, enkefaliineja, P-substanssia, neurotensiiniä, oksytosiinia, bradykiniiniä (BK). Geeniä ilmenee duodenumissa, munuaisessa ja 8 muussa kudoksessa. Neprilysiinillä on vaihtoehtoisia nimiä monta, mutta  suositeltu nimi on neprilysiini(NEP). Se tunnetaan  myös mm.  atriolysiininä,   yleisenä  akuuttin lymfosyyttileukemian antigeenina (CALLA)
kalvon metallo-endopeptidaasina (MME), neutraalina endopeptidaasina (NEP), enkefalinaasina, CD 10 (Cluster of Differentiation 10), iho-fibriblastielastaasina (SFE)  ja muitakin nimiä on ( kts. alla)

PubMed:
Official Symbol MME
  membrane metalloendopeptidase
Also known as
NEP; SFE; CD10; CALLA; CMT2T; SCA43
Summary
The protein encoded by this gene is a type II transmembrane glycoprotein and a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). The encoded protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL. This protein is not restricted to leukemic cells, however, and is found on a variety of normal tissues. The protein is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. [provided by RefSeq, Aug 2017]
Expression
Biased expression in duodenum (RPKM 88.5), kidney (RPKM 83.7) and 8 other tissues See more
Preferred Names
neprilysin
Names
atriopeptidase
common acute lymphocytic leukemia antigen
membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10)
membrane metallo-endopeptidase variant 1
membrane metallo-endopeptidase variant 2
neprilysin-390
neprilysin-411
neutral endopeptidase 24.11
skin fibroblast elastase
Neprilysiiniin  liittyvää lisätietoa PubMed artikkeleista.

Related articles in PubMed

See citations in PubMed for homologs of this gene provided by HomoloGe
 GeneRIF
 Tietoja  Neprilysiiniproteiinista
 https://www.ncbi.nlm.nih.gov/protein/NP_000893.2
Tässä on isoformi a (1..750 amiohappoa) TM kohta merkattutummalla (29..51) ,
Aktiivikohta merkattu isoilla kirjaimilla. 543N, 544A, 581V, 584H, 585E, 588H, 647E, 690F, 691A 712H, 718R.
Zinkkiä sitova kohta m, kolme aminohappoa osuu aktiiviin kohtaan, tummalla merkatut. 
Näkyy olevan yksi  motiivi llxxl  (674-680) (lie tumareseptori?) 
peptidista koko mitalta  79-748  on M12 peptidaasiperheen M12 endoteliinia konvertoiva entsyymi I (ECE-1) .
N-terminaalinen sytoplasminen osa:
1 mgksesqmdi tdintpkpkk kqrwtple
ORIGIN      
        1 mgksesqmdi tdintpkpkk kqrwtpleis lsvlvlllti iavtmialya tyddgickss
       61 dciksaarli qnmdattepc tdffkyacgg wlkrnvipet ssrygnfdil rdelevvlkd
      121 vlqepktedi vavqkakaly rscinesaid srggepllkl lpdiygwpva tenweqkyga
      181 swtaekaiaq lnskygkkvl inlfvgtddk nsvnhvihid qprlglpsrd yyectgiyke
      241 actayvdfmi svarlirqee rlpidenqla lemnkvmele keianatakp edrndpmlly
      301 nkmtlaqiqn nfsleingkp fswlnftnei mstvnisitn eedvvvyape yltklkpilt
      361 kysardlqnl mswrfimdlv sslsrtykes rnafrkalyg ttsetatwrr canyvngnme
      421 navgrlyvea afageskhvv edliaqirev fiqtlddltw mdaetkkrae ekalaikeri
      481 gypddivsnd nklnneylel nykedeyfen iiqnlkfsqs kqlkklrekv dkdewisgaa
      541 vvNAfyssgr nqivfpagil qppffsaqqs nslnyggigm VigHEitHgf ddngrnfnkd
      601 gdlvdwwtqq sasnfkeqsq cmvyqygnfs wdlaggqhln gintlgEnia dngglgqayr
      661 ayqnyikkng eekllpgldl nhkqlfflnF Aqvwcgtyrp eyavnsiktd vHspgnfRii
      721 gtlqnsaefs eafhcrknsy mnpekkcrvw
//


Tietoja Neprilysiinin  perheestä "M13".
Metallopeptidase family M13 includes neprilysin (NEP) and other members: 

M13 family of metallopeptidases includes
 neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11),
endothelin-converting enzyme I (ECE-1, EC 3.4.24.71),
 erythrocyte surface antigen KELL (ECE-3),
phosphate-regulating gene on the X chromosome (PHEX),
 soluble secreted endopeptidase (SEP), and
 damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE).

 These proteins consist of a short N-terminal cytoplasmic domain,
 a single transmembrane helix,
and a larger C-terminal extracellular domain containing the active site.
Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity.

NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P (SP), enkephalins, cholecystokinin (CCK), neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD).

 ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyses bradykinin, substance P, neurotensin and Abeta.  

Endothelin-1 overproduction has been implicated in various diseases, including stroke, asthma, hypertension, and cardiac and renal failure.

 Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A.

PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets.

 ECEL1 is a brain metalloprotease involved in the critical role in the nervous regulation of the respiratory system, while

DINE (damage induced neuronal endopeptidase) is abundantly expressed in the hypothalamus and its expression responds to nerve injury as well.

 Thus, majority of these M13 proteases are prime therapeutic targets for selective inhibition.

 https://www.ncbi.nlm.nih.gov/pubmed

Liekö yhteyttä  ylläolevilla tekijöillä respiraation kerebraaliseen säätelyyn? Katsotaan,mitä tiede löytää lähi tulevaisuudesa.

2020 Feb 3;112:95-106. doi: 10.1016/j.neubiorev.2020.02.001. [Epub ahead of print]
Respiratory regulation & interactions with neuro-cognitive circuitry.
Abstract
It is increasingly being recognized that active control of breathing - a key aspect of ancient Vedic meditative practices, can relieve stress and anxiety and improve cognition. However, the underlying mechanisms of respiratory modulation of neurophysiology are just beginning to be elucidated. Research shows that brainstem circuits involved in the motor control of respiration receive input from and can directly modulate activity in subcortical circuits, affecting emotion and arousal. Meanwhile, brain regions involved in the sensory aspects of respiration, such as the olfactory bulb, are like-wise linked with wide-spread brain oscillations; and perturbing olfactory bulb activity can significantly affect both mood and cognition. Thus, via both motor and sensory pathways, there are clear mechanisms by which brain activity is entrained to the respiratory cycle. Here, we review evidence gathered across multiple species demonstrating the links between respiration, entrainment of brain activity and functional relevance for affecting mood and cognition. We also discuss further linkages with cardiac rhythms, and the potential translational implications for biorhythm monitoring and regulation in neuropsychiatric disorders.







 ----------------Päivitys 26.2. 2020